Sign in

    Laura Engle

    Senior Advisor of Research at Stonegate Securities

    Laura Engel is a Senior Advisor of Research at Stonegate Securities, specializing in equity research with a focus on covering niche healthcare and life sciences companies, including Sonoma Pharmaceuticals. She has contributed to Stonegate’s research team since at least 2022, where she provides detailed analysis and engages with management teams to enhance client investment decisions. Over her career, Engel has demonstrated rigorous research acumen, leveraging her CPA credentials to deliver actionable investment insights, although public performance metrics and platform rankings are not widely reported. Prior to her current position, she built a strong foundation in financial analysis and accounting, which complements her expertise in the securities industry and is reflected in her active FINRA registration and certifications.

    Laura Engle's questions to Sonoma Pharmaceuticals (SNOA) leadership

    Laura Engle's questions to Sonoma Pharmaceuticals (SNOA) leadership • Q3 2018

    Question

    Laura Engle from Stonegate Securities asked for clarification on the Invekra manufacturing deal, specifically its contractual end date and margin impact. She also inquired about the company's cash burn relative to its cash position and potential future funding needs to reach profitability. Finally, she questioned if there were plans to seek U.S. approval for products recently approved in the UAE.

    Answer

    CFO Robert Miller clarified that the contractual obligation to manufacture for Invekra at a 6% margin ends in October 2018, at which point Sonoma can renegotiate terms. He also stated that the company's cash burn is expected to decrease significantly in the upcoming quarters as it moves toward profitability. CEO James Schutz addressed the UAE approvals, explaining that while desirable, obtaining similar broad indications from the FDA in the U.S. is highly unlikely due to different regulatory standards, and the company is not actively pursuing them.

    Ask Fintool Equity Research AI